Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Wednesday 26 April 2017, 10.00 – 14:15

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Professor Gary McVeigh (Chair) Present for all notes
2. Dr Lindsay Smith (Vice Chair) Present for all notes
3. Dr Aomesh Bhatt Present for all notes
4. Professor David Bowen Present for all notes
5. Dr Matthew Bradley Present for all notes
6. Dr Ian Davidson Present for all notes
7. Professor Simon Dixon Present for all notes
8. Professor Rachel Elliott Present for all notes
9. Mrs Gillian Ells Present for all notes
10. Dr Rebecca Harmston Present for all notes
11. Dr Peter Hall Present for all notes
12. Sumithra Maheswaran Present for all notes
13. Dr David Meads Present for all notes
14. Pam Rees Present for all notes
15. Mr William Turner Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Professor Peter Clark CDF Clinical Lead, NHS England Present for all notes

Dr Keith Cooper Southampton Health Technology Assessments Centre Present for notes 1 to 12

Ross Dent Technical Analyst, National Institute for Health and Care Excellence Present for all notes

Jenna Dilkes Project Manager, National Institute for Health and Care Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Nominator</th>
<th>Notes Present For</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Geoff Frampton</td>
<td>Southampton Health Technology Assessments Centre</td>
<td>1 to 12</td>
</tr>
<tr>
<td>Dr Syed Hussain</td>
<td>Clinical Expert, nominated by Roche Products, BUG, Royal College of Physicians</td>
<td>1 to 12</td>
</tr>
<tr>
<td>Allen Knight</td>
<td>Patient Expert, nominated by Action Bladder UK</td>
<td>1 to 12</td>
</tr>
<tr>
<td>Helen Knight</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>all notes</td>
</tr>
<tr>
<td>Teri Morgan</td>
<td>Patient expert, nominated by Fight Bladder Cancer</td>
<td>1 to 12</td>
</tr>
<tr>
<td>Professor Thomas Powles</td>
<td>Clinical expert, nominated by Roche Products</td>
<td>1 to 9</td>
</tr>
<tr>
<td>Mandy Tonkinson</td>
<td>Administrator, National Institute for Health and Care Excellence</td>
<td>all notes</td>
</tr>
<tr>
<td>Ian Watson</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>all notes</td>
</tr>
</tbody>
</table>

**Non-public observers:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Nominator</th>
<th>Notes Present For</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karyo Angeloudis</td>
<td>Analyst, PASUL National Institute for Health and Care Excellence</td>
<td>all notes</td>
</tr>
<tr>
<td>Steve Estevao</td>
<td>Analyst, PASUL National Institute for Health and Care Excellence</td>
<td>all notes</td>
</tr>
<tr>
<td>Ann Greenwood</td>
<td>Senior Medical Editor, National Institute for</td>
<td>all notes</td>
</tr>
</tbody>
</table>
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.

2. Apologies were received from Susan Dutton, Professor Paula Ghaneh, Malcolm Oswald, Professor Femi Oyebode and Dr Paula Parvulescu.

Any other Business

3. None

Appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy [ID939]

Part 1 – Open session

4. The Chair welcomed the invited experts, Dr Keith Cooper, Dr Geoff Frampton, Dr Syed Hussain, Allen Knight, Teri Morgan and Professor Thomas Powles to the meeting and they introduced themselves to the Committee.

5. The Chair welcomed company representatives from Roche Products to the meeting.

6. The Chair asked all Committee members to declare any relevant interests

6.1. Dr Lindsay Smith, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Professor Simon Dixon, Professor Rachel Elliott, Mrs Gillian Ellis, Rebecca Harmston, Sumithra Maheswaran, Dr David Meads and Pam Rees all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial
interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.

6.2. Professor Simon Dixon declared a non-specific non-personal financial interest as he is the Director of a Health Economics Unit that has undertaken work for comparator companies.

6.2.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.

6.3. Williams Turner declared a non-specific personal financial interest as his wife holds shares in Worldwide Healthcare Trust PLC.

6.3.1 It was agreed that this declaration would prevent William Turner from participating in this section of the meeting.

6.4. Dr Peter Hall declared a non-specific non-personal financial interest as the University of Edinburgh has received fees from Roche for his participation in an advisory board.

6.4.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

7. The Chair asked all NICE Staff to declare any relevant interests.

7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.

8. The Chair asked all other invited guests to declare their relevant interests.

8.1. Dr Keith Cooper, Dr Geoff Frampton and Teri Morgan all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.

8.2. Allen Knight declared a non-specific personal non-personal financial interest as Action for Bladder Cancer had received funding from the pharmaceutical industry.

8.2.1 It was agreed that this declaration would not prevent Allen Knight from participating in this section of the meeting.

8.3. Professor Syed Hussain declared a non-specific personal financial interest as he had received funding for attending advisory boards from the company and comparator companies.

8.3.1 It was agreed that this declaration would not prevent Professor Syed Hussain from participating in this section of the meeting.
8.4. Professor Thomas Powles declared a non-specific personal financial interest as he had received funding when acting in an advisory capacity for the company and comparator companies.

8.4.1. It was agreed that this declaration would not prevent Professor Thomas Powles from participating in this section of the meeting.

9. The Chair introduced the lead team, Rebecca Harmston, Sumithra Maheswaran and Dr David Mead who gave presentations on the clinical effectiveness and cost effectiveness of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. The Committee continued to discuss the clinical and cost effectiveness of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.

13.1. The committee decision was based on consensus.

14. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

15. Wednesday 31 May 2017, from 10am -5pm at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.